Ryan Cassaday
@RyanCassaday
Followers
274
Following
387
Statuses
354
Husband of Dr. Emily Stevens MD PhD. ALL Doctor. Product of 2 UW's. Tweets are mine and do not constitute medical advice.
Seattle, WA
Joined April 2016
Thanks, @OncLive. Enjoyed getting to highlight some clinically relevant abstracts on ALL from #ASH24 in this episode of #OncLiveOnAir. I’ve always thought I had a great face for radio. 🤓 #leusm
In this episode of #OncLiveOnAir, Ryan Cassaday, MD, of Fred Hutch provides insight on several trials assessing blinatumomab in B-cell acute lymphoblastic leukemia. @RyanCassaday @fredhutch #leusm #hematology LISTEN:
0
1
1
Honored to be a part of the great line-up for this terrific course! Thank you, @NitinJainMD and others for putting this together! #leusm
👉👉👉 Excited to welcome you to the inaugural Pan Pacific Leukemia Conference in Maui, Hawaii, July 15-18, 2025. Join collaboration of University of Nebraska and MD Anderson cc @DrJulieVose @VijayaRBhatt1 @mkonople @lymphomaphilia @DrHKantarjian Registration link Please join! Thank you
0
1
2
RT @fredhutch: 50 years of Fred Hutch! Founded in 1975 to honor a brother, Fred Hutch Cancer Center pursued bold science, pioneered a cure…
0
5
0
RT @RahulBanerjeeMD: Learning from @RyanCassaday at @btfoundation #BTFHem2025 What’s new in auto-CAR delivery besides novel targets? A lot…
0
2
0
RT @btfoundation: It's happening! @RolandBWalter and @RyanCassaday from @fredhutch @UWMedicine talk about acute leukemia at #BTFHemBreast25…
0
1
0
I will be speaking @btfoundation “Best of Hematology and Breast Cancer 2025” on January 3-4, 2025 in Seattle. My talk will be on Acute Lymphoblastic Leukemia You can register here: #leusm
0
3
6
RT @emilyliangmd: Thanks to @BloodAdvances for publishing our work to develop and validate the Early ICAHT Prediction Models (eIPMs)! The e…
0
9
0
@AaronGoodman33 Technically, approval is agnostic of lineage. So should be available for ALL, MPAL, and AUL, too, all of which can have KMT2A rearrangement!
0
0
2
Treat adults with ALL? Check out our practical review on brexu-cel! Includes latest data from #ROCCA, @CIBMTR, and ZUMA-3 plus how it fits with recent approval of obe-cel. @fredhutch @UWMedicine #leusm #CARTcell
0
1
6
@MarkGeyerMD @RahulBanerjeeMD I’m just gonna leave this here: #ASH23 analysis from #ROCCA showing latest onset of new ICANS symptoms with brexu-cel in adults with R/R ALL was 21 days. 8-wk driving restrictions not supported by data, are vestiges of early CAR-T trials!
0
1
3
RT @drjgauthier: Exciting news for adult B-ALL patients! @US_FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-…
0
18
0
@ChenyuLinMD @challenlab @Bloodneoplasia If so, consider keeping me posted, please. We desperately need new options when standard chemo fails in this disease.
0
0
0
Proud that @fredhutch and @UWMedicine are part of the “30+ centers” who contributed to this work. Thanks to the outstanding staff at the Bezos Family Immunotherapy Clinic, who cared for these patients. Now led by my friend and colleague, @mshadman Great work, @RoloffGreg !
Topline results studying brexu-cel in relapsed B-ALL, now out @JCO_ASCO. My thanks to @LoriMuffly and partners from 30+ centers driven to answer ?s in a rare disease space. More to come. @bshah @MoffittNews @UChicagoHemOnc
0
1
12
RT @mshadman: BMT/Immunotherapy fellowship at @fredhutch . Accepting applications now! A great clinical and research opportunity for those…
0
9
0
@UWMedicine @fredhutch 3. Identified other abnormalities that impacted prognosis, like ETV6 loss and ZCCHC7 loss. We speculate on potential mechanisms and highlight need for further work to tease these out better. Thanks to our coauthors, lab staff, and (of course) patients we treated over these yrs.
0
0
0